Goldman Sachs Downgrades Nektar Therapeutics (NKTR) to Sell

April 18, 2022 8:34 AM EDT
Get Alerts NKTR Hot Sheet
Price: $3.51 +3.85%

Rating Summary:
    12 Buy, 11 Hold, 5 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 8 | Down: 9 | New: 24
Join SI Premium – FREE

Goldman Sachs analyst Chris Shibutani downgraded Nektar Therapeutics (NASDAQ: NKTR) from Neutral to Sell with a price target of $3.00.

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $6.16 yesterday.

You May Also Be Interested In

Related Categories